Comparison of anti-IL-6 receptor and JAK inhibitors in patients with rheumatoid arthritis from the real-world practice FIRST registry
Authors' conclusion
IL-6Ri offers a superior balance of efficacy and safety compared with JAKis for RA patients unresponsive to one bDMARD. However, JAKis may suit patients who do not respond to multiple bDMARDs.
Study context
- Population
- Patients with rheumatoid arthritis (RA) with inadequate response to biological disease-modifying antirheumatic drug (bDMARD), real-world FIRST registry
- Exposure
- JAKi vs IL-6Ri as second or subsequent molecular-targeted therapy
- Outcome
- CDAI remission rate
- Follow-up
- Week 26
Methodological detailsregistry-based (FIRST registry), propensity score-based inverse probability of treatment weighting, growth mixture modeling
- Registry-based (FIRST registry)
- Propensity score-based inverse probability of treatment weighting
- Growth mixture modeling
Main finding
As reported in the abstract
CDAI remission
- Remission rate higher with Janus kinase inhibitors (JAKis) than IL-6Ri
- PS-IPTW
Observational data: associations, not effects.
Further findings
CDAI remission, failure of one bDMARD (subgroup) · week 26 · no significant difference
P = 0.21
Clinical disease activity index (CDAI) remission, failure of ≥2 bDMARDs (subgroup) · week 26
- Remission rate higher with JAKis than IL-6Ri
Efficacy of IL-6Ri by number of failed bDMARDs
- IL-6Ri greater efficacy after single vs multiple ineffective bDMARDs
- CDAI trajectories divided into four by growth mixture modeling
Safety
Infection incidence
- Higher with JAKis than IL-6Ri
Original publication
Comparison of anti-IL-6 receptor and JAK inhibitors in patients with rheumatoid arthritis from the real-world practice FIRST registry. Rheumatology (Oxford). Published 18 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →